• Publications
  • Influence
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
TLDR
This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add‐on to metformin plus sulphonylurea in patients with T2DM.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L
TLDR
Compared withiGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
Aim:  To determine the efficacy and tolerability of PHX1149, a novel dipeptidyl peptidase‐4 (DPP4) inhibitor, in patients with type 2 diabetes.
VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES: PREVALENCE AND COMORBIDITIES IN 6 COUNTRIES OF LATIN AMERICA (A COHORT OF THE DISCOVER STUDY PROGRAM).
TLDR
It is shown that patients with Type 2 diabetes in Latin America are not reaching their glucose, lipids, blood pressure and weight targets, and the need for more aggressive risk factor screening as well as treatment is highlighted.
...
1
2
3
...